| |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL |
| |
OMB Number: 3235-0058
Expires: September
30, 2028 Estimated average burden hours per response 2.50 |
| |
FORM 12b-25 |
SEC FILE NUMBER
|
| |
NOTIFICATION OF LATE FILING |
CUSIP NUMBER
|
(Check
One): ¨ Form 10-K ¨ Form
20-F ¨ Form 11-K x
Form 10-Q ¨ Form 10-D ¨
Form N-CEN ¨ Form N-CSR
For Period Ended: September
30, 2026
¨ Transition Report on Form 10-K
¨ Transition Report on Form 20-F
¨
Transition Report on Form 11-K
¨
Transition Report on Form 10-Q
For the Transition Period
Ended: ________________________________________________________________
|
Read Instruction
(on back page) Before Preparing Form. Please Print or Type.
Nothing in this
form shall be construed to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification
relates:
PART
I — REGISTRANT INFORMATION
Full Name of Registrant: CytoSorbents Corporation
Former Name if Applicable:
Address of
Principal Executive Office (Street and Number): 305 College Road East
City,
State and Zip Code: Princeton, New Jersey 08540
PART
II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
| x |
(a) The reasons described
in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could
not be filed within the prescribed time period.
CytoSorbents
Corporation (the “Company”) is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q
for the quarter ended September 30, 2026 (the “Form 10-Q”) within the prescribed time period. The Company requires additional
time to work with its independent registered public accounting firm to complete its evaluation of the calculation of non-cash foreign
currency exchange gains and losses recorded during the nine months ended September 30, 2026, and the related accounting treatment. As
a result, the Form 10-Q cannot be filed within the prescribed time period and will be filed on or before the fifth calendar day following
the prescribed due date.
PART IV — OTHER INFORMATION
| (1) |
Name and telephone number of person to contact in regard to this notification. |
| Peter J. Mariani |
|
(732) |
|
329-8885 |
| (Name) |
|
(Area Code) |
|
(Telephone Number) |
| (2) |
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s). |
| |
Yes x No ¨ |
| |
|
| (3) |
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? |
| |
Yes ¨ No x |
| |
|
| |
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made. |
CytoSorbents Corporation
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
| Date |
November 17, 2026 |
|
By |
/s/ Peter J. Mariani |
| |
|
|
Peter J. Mariani
Chief Financial Officer |